Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Single Centre, Enabling Study to Investigate the Optimum Method for Use of Intradermal Substance P as a Challenge Agent in Healthy Participants

NCT04676763 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT04676763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04676763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Single Centre, Enabling Study to Investigate the Optimum Method for Use of Intradermal Substance P as a Challenge Agent in Healthy Participants
Lead sponsor
GlaxoSmithKline
Phase
Not applicable
Overall status
Completed
Start date
March 2, 2021
Completion date
July 21, 2021
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

skin diseases